Biologic injections for osteoarthritis and articular cartilage damage: can we modify disease?

Shi, Weilong J.; Tjoumakaris, Fotios P.; Lendner, Mayan; Freedman, Kevin B.

doi:10.1080/00913847.2017.1357421

Cited by 28 publications

(17 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

mentioning

confidence: 99%

“…2,15 The strategy of intra-articular (IA) injection of MSCs may be most appropriate early in the development of OA to modulate the joint environment, limit catabolic processes, contribute to repair, and promote anabolic responses. 41,46 Evidence for the clinical use of IA MSCs to treat OA was first established in small animal preclinical models. IA injection of allogenic bone marrow-derived MSCs (BMSCs) mitigated the histologic progression of knee OA in a rat model after medial meniscectomy and ACL transection.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Integrin α10β1-Selected Mesenchymal Stem Cells Mitigate the Progression of Osteoarthritis in an Equine Talar Impact Model

et al. 2020

View full text Add to dashboard Cite

Background: Early intervention with mesenchymal stem cells (MSCs) after articular trauma has the potential to limit progression of focal lesions and prevent ongoing cartilage degeneration by modulating the joint environment and/or contributing to repair. Integrin α10β1 is the main collagen type II binding receptor on chondrocytes, and MSCs that are selected for high expression of the α10 subunit have improved chondrogenic potential. The ability of α10β1-selected (integrin α10high) MSCs to protect cartilage after injury has not been investigated. Purpose: To investigate integrin α10high MSCs to prevent posttraumatic osteoarthritis in an equine model of impact-induced talar injury. Study Design: Controlled laboratory study. Methods: Focal cartilage injuries were created on the tali of horses (2-5 years, n = 8) by using an impacting device equipped to measure impact stress. Joints were treated with 20 × 106 allogenic adipose-derived α10high MSCs or saline vehicle (control) 4 days after injury. Synovial fluid was collected serially and analyzed for protein content, cell counts, markers of inflammation (prostaglandin E2, tumor necrosis factor α) and collagen homeostasis (procollagen II C-propeptide, collagen type II cleavage product), and glycosaminoglycan content. Second-look arthroscopy was performed at 6 weeks, and horses were euthanized at 6 months. Joints were imaged with radiographs and quantitative 3-T magnetic resonance imaging. Postmortem examinations were performed, and India ink was applied to the talar articular surface to identify areas of cartilage fibrillation. Synovial membrane and osteochondral histology was performed, and immunohistochemistry was used to assess type I and II collagen and lubricin. A mixed effect model with Tukey post hoc and linear contrasts or paired t tests were used, as appropriate. Results: Integrin α10high MSC-treated joints had less subchondral bone sclerosis on radiographs ( P = .04) and histology ( P = .006) and less cartilage fibrillation ( P = .04) as compared with control joints. On gross pathology, less India ink adhered to impact sites in treated joints than in controls, which may be explained by the finding of more prominent lubricin immunostaining in treated joints. Prostaglandin E2 concentration in synovial fluid and mononuclear cell synovial infiltrate were increased in treated joints, suggesting possible immunomodulation by integrin α10high MSCs. Conclusion: Intra-articular administration of integrin α10high MSCs is safe, and evidence suggests that the cells mitigate the effects of joint trauma. Clinical Relevance: This preclinical study indicates that intra-articular therapy with integrin α10high MSCs after joint trauma may be protective against posttraumatic osteoarthritis.

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

Integrin α10β1-Selected Mesenchymal Stem Cells Mitigate the Progression of Osteoarthritis in an Equine Talar Impact Model

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Therefore, further high-quality studies for OA with high internal and external validity are still required. In addition, Shi et al compared the clinical results of platelet-rich plasma (PRP) and MSCs treatments for osteoarthritis of the knee in a systematic review and pointed out MSCS provide more significant disease therapeutic effect [47].…”

Section: Mscs In the Treatment Of Osteoarthritismentioning

confidence: 99%

Clinical Applications of Mesenchymal Stromal Cells (MSCs) in Orthopedic Diseases

Yang¹,

Fang²,

Xu³

et al. 2019

Stromal Cells - Structure, Function, and Therapeutic Implications

View full text Add to dashboard Cite

Mesenchymal stromal cells (MSCs) have the capacity for self-renewal and multi-lineage differentiation, have many advantages over other cells, and are thought to be one of the most promising cell sources for cell-based treatments. In fact, MSCs have already been widely applied in clinics as a treatment for numerous disorders, including orthopedic diseases, such as bone fracture, articular cartilage injury, osteoarthritis (OA), femoral head necrosis, degenerative disc, meniscus injury, osteogenesis imperfecta (OI), and other systemic bone diseases. With the progressions in R&D, the safety and efficacy of MSC-based treatments in orthopedic diseases have been largely recognized, but many challenges still exist. In this chapter, we intend to briefly update the recent progressions and discuss the potential issues in the target areas. Hopefully, our discussion would be helpful not only for the clinicians and the researchers in the specific disciplines but also for the general audiences.

show abstract

“…Sua aplicação na Medicina tem início da década de 80, com aprovação para o uso intra-articular, indicado como redutor inflamatório, (FIG. 8), Synvisc®, porém, após mais de uma década do uso para tal fim, diversos estudos não demonstraram essa ação anti-inflamatória, até porque as alterações inflamatórias do líquido sinovial não são iguais aos exudatos inflamatórios clássicos, o que dificulta a avaliação de agentes desinflamatórios, Isto determinou a mudança de sua indicação e propriedade terapêutica para visco reposição, consequentemente, visco terapia, havendo, dentro dessa proposta, melhora da dor e da função articular a médio e longo prazo, quando realizadas aplicações seriadas (34). Nos primórdios de 1990, sua utilização na prática médica com produtos pioneiros para correções estéticas da face, As ilustrações abaixo apresentam dois produtos da indústria farmacêutica muito utilizado na prática médica, constituídos de Ac.…”

Section: áCido Hialurônicounclassified

Uso de gel tri composto, <i>\"TRIGEL\"</i> (titânio + PVA + ac. hialurônico) associado ou não com células-tronco, no reparo da lesão osteo cartilaginosa: modelo animal

Ribeiro¹

View full text Add to dashboard Cite

Biologic injections for osteoarthritis and articular cartilage damage: can we modify disease?

Abstract: Current data suggests that, of the two treatments, MSC provides more significant disease modifying effect; however, further research needs to be done to compare these two treatments and determine if there is a synergetic effect when combined.

Cited by 28 publications

References 48 publications

Integrin α10β1-Selected Mesenchymal Stem Cells Mitigate the Progression of Osteoarthritis in an Equine Talar Impact Model

Integrin α10β1-Selected Mesenchymal Stem Cells Mitigate the Progression of Osteoarthritis in an Equine Talar Impact Model

Clinical Applications of Mesenchymal Stromal Cells (MSCs) in Orthopedic Diseases

Uso de gel tri composto, <i>\"TRIGEL\"</i> (titânio + PVA + ac. hialurônico) associado ou não com células-tronco, no reparo da lesão osteo cartilaginosa: modelo animal

Contact Info

Product

Resources

About